Clinical Trial Update: Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting

View source ↗

Summary

This completed trial update describes how Nexavar (sorafenib) was dosed in renal cell carcinoma patients in real-world clinical settings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Status: COMPLETED